Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver
- 27 January 2010
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 2 (16) , 16ra7
- https://doi.org/10.1126/scitranslmed.3000389
Abstract
The ability of certain breast cancers to resist a tyrosine kinase inhibitor drug may be overcome with high intermittent doses.Keywords
This publication has 43 references indexed in Scilit:
- A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid MalignanciesClinical Cancer Research, 2009
- Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicityOncogene, 2008
- Mechanism of Activation and Inhibition of the HER4/ErbB4 KinaseStructure, 2008
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 2007
- Lapatinib Antitumor Activity Is Not Dependent upon Phosphatase and Tensin Homologue Deleted on Chromosome 10 in ErbB2-Overexpressing Breast CancersCancer Research, 2007
- Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Nature, 2007
- Mechanisms of cutaneous toxicities to EGFR inhibitorsNature Reviews Cancer, 2006
- An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor ReceptorPublished by Elsevier ,2006
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987